Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D. - Effect of Febuxostat on Flow Mediated Diameter. (FFMD-5D study)

We randomly assigned 53 hemodialysis patients with hyperuricemia to a febuxostat (10mg daily) group and a control group. Flow-mediated dilation increased from 5.3% to 8.9 in the febuxostat group but did not change significantly in the control group. Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure. No significant differences were observed in the control group.